Brain Injury Biomarkers May Improve the Predictive Power of the IMPACT Outcome Calculator
- 10 June 2012
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Neurotrauma
- Vol. 29 (9), 1770-1778
- https://doi.org/10.1089/neu.2011.2127
Abstract
Outcome prediction following severe traumatic brain injury (sTBI) is a widely investigated field of research. A major breakthrough is represented by the IMPACT prognostic calculator based on admission data of more than 8500 patients. A growing body of scientific evidence has shown that clinically meaningful biomarkers, including glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase-L1 (UCH-L1), and αII-spectrin breakdown product (SBDP145), could also contribute to outcome prediction. The present study was initiated to assess whether the addition of biomarkers to the IMPACT prognostic calculator could improve its predictive power. Forty-five sTBI patients (GCS score≤8) from four different sites were investigated. We utilized the core model of the IMPACT calculator (age, GCS motor score, and reaction of pupils), and measured the level of GFAP, UCH-L1, and SBDP145 in serum and cerebrospinal fluid (CSF). The forecast and actual 6-month outcomes were compared by logistic regression analysis. The results of the core model itself, as well as serum values of GFAP and CSF levels of SBDP145, showed a significant correlation with the 6-month mortality using a univariate analysis. In the core model, the Nagelkerke R2 value was 0.214. With multivariate analysis we were able to increase this predictive power with one additional biomarker (GFAP in CSF) to R2=0.476, while the application of three biomarker levels (GFAP in CSF, GFAP in serum, and SBDP145 in CSF) increased the Nagelkerke R2 to 0.700. Our preliminary results underline the importance of biomarkers in outcome prediction, and encourage further investigation to expand the predictive power of contemporary outcome calculators and prognostic models in TBI.Keywords
This publication has 39 references indexed in Scilit:
- Biokinetic Analysis of Ubiquitin C-Terminal Hydrolase-L1 (UCH-L1) in Severe Traumatic Brain Injury Patient BiofluidsJournal of Neurotrauma, 2011
- αII-Spectrin Breakdown Products (SBDPs): Diagnosis and Outcome in Severe Traumatic Brain Injury PatientsJournal of Neurotrauma, 2010
- Ubiquitin C‐terminal hydrolase‐L1 as a biomarker for ischemic and traumatic brain injury in ratsEuropean Journal of Neuroscience, 2010
- Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury*Critical Care Medicine, 2010
- αII-Spectrin Breakdown Product Cerebrospinal Fluid Exposure Metrics Suggest Differences in Cellular Injury Mechanisms after Severe Traumatic Brain InjuryJournal of Neurotrauma, 2009
- Classification of Traumatic Brain Injury for Targeted TherapiesJournal of Neurotrauma, 2008
- A systematic review finds methodological improvements necessary for prognostic models in determining traumatic brain injury outcomesJournal of Clinical Epidemiology, 2008
- Predicting Outcome after Traumatic Brain Injury: Development and Validation of a Prognostic Score Based on Admission CharacteristicsJournal of Neurotrauma, 2005
- GFAP Versus S100B in Serum after Traumatic Brain Injury: Relationship to Brain Damage and OutcomeJournal of Neurotrauma, 2004
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001